ArticleInternational journal of immunopathology and pharmacology
Oral booster probiotic bifidobacteria in SARS-COV-2 patients.
Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Probiotics for preventing or treating COVID-19; a systematic review of research evidence and meta-analyses of efficacy for preventing death, severe disease, or disease progression.Wellcome open research · 2022Pooled it
- Systematic Review on COVID-19 Readmission and Risk Factors: Future of Machine Learning in COVID-19 Readmission Studies.Frontiers in public health · 2022Pooled it
- The Role of Probiotics and Their Postbiotic Metabolites in Post-COVID-19 Syndrome.Molecules (Basel, Switzerland) · 2025Review
- Exploring the Therapeutic Landscape of Probiotics in Enteric and Respiratory Viral Infections.Probiotics and antimicrobial proteins · 2025Review
- Gut microbiome in gastrointestinal neoplasms: from mechanisms to precision therapeutic strategies.Gut pathogens · 2025Review
- Role of Bifidobacterium animalis subsp. lactis BB-12 in mice with acute pancreatitis.AMB Express · 2025Article
- The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.eLife · 2025Observational
- Partially hydrolyzed guar gum attenuates symptoms and modulates the gut microbiota in a model of SARS-CoV-2 infection.Gut microbiome (Cambridge, England) · 2025Article
- "Feed a Cold, Starve a Fever?" A Review of Nutritional Strategies in the Setting of Bacterial Versus Viral Infections.Current nutrition reports · 2024Review
- Bifidobacteria shape antimicrobial T-helper cell responses during infancy and adulthood.Nature communications · 2023Article
- The Role of Bifidobacterium in COVID-19: A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Intratumoural microbiota: from theory to clinical application.Cell communication and signaling : CCS · 2023Review
- Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.Microbial cell factories · 2023Article
- Akkermansia muciniphila exerts immunomodulatory and anti-inflammatory effects on gliadin-stimulated THP-1 derived macrophages.Scientific reports · 2023Article
- Gut microbiota and COVID-19: A systematic review.Health science reports · 2023Article
- Review
- Gut-brain pathogenesis of post-acute COVID-19 neurocognitive symptoms.Frontiers in neuroscience · 2023Article
- The Gut Microbiome of Children during the COVID-19 Pandemic.Microorganisms · 2022Review
- Respiratory and Intestinal Microbiota in Pediatric Lung Diseases-Current Evidence of the Gut-Lung Axis.International journal of molecular sciences · 2022Review
- Effective Regulation of Gut Microbiota With Probiotics and Prebiotics May Prevent or Alleviate COVID-19 Through the Gut-Lung Axis.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral booster-single strain probiotic bifidobacteria could be a potential strategy for SARS-CoV-2. This study aims to evaluate the role of oral probiotic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.